<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575861</url>
  </required_header>
  <id_info>
    <org_study_id>2000</org_study_id>
    <secondary_id>Critical Therapeutics, Inc.</secondary_id>
    <nct_id>NCT00575861</nct_id>
  </id_info>
  <brief_title>Zileuton and Exhaled Nitric Oxide in Asthmatics</brief_title>
  <official_title>Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelb, Arthur F., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelb, Arthur F., M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair
      250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased
      total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven
      pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor
      by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nitric oxide gas exchange including total exhaled nitric oxide, bronchial and alveolar nitric oxide</measure>
    <time_frame>2 hr to 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>expiratory spirometry and asthma symptom Juniper score</measure>
    <time_frame>2 hr to 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advair 250/50 (baseline) fluticasone/salmeterol 250/50</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zileuton</intervention_name>
    <description>zileuton (Zyflo) 600mg qid for 2hr and for 30 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>zyflo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking

          -  Moderate to severe persistent asthmatics

          -  Clinically stable X 6 weeks on Advair 250/50 bid for at least 12 months

        Exclusion Criteria:

          -  No leukotriene synthesis inhibitors or receptor antagonists for 6 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arthur F Gelb Medical Corporation</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gelb AF, Taylor CF, Simmons M, Shinar C. Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. Pulm Pharmacol Ther. 2009 Dec;22(6):516-21. doi: 10.1016/j.pupt.2009.05.003. Epub 2009 May 23.</citation>
    <PMID>19467341</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest. 2006 Jun;129(6):1492-9.</citation>
    <PMID>16778266</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein MJ, Epstein JD, Zamel N. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med. 2004 Oct 1;170(7):737-41. Epub 2004 Jun 30.</citation>
    <PMID>15229098</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>December 18, 2007</last_update_submitted>
  <last_update_submitted_qc>December 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2007</last_update_posted>
  <responsible_party>
    <name_title>Arthur F. Gelb MD</name_title>
    <organization>Arthur F. Gelb Medical Corporation</organization>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>nitric oxide gas exchange</keyword>
  <keyword>lung function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Zileuton</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

